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Background and aims: The pharmacological treatment of individuals with attention deﬁcit hyperactivity disorder
(ADHD) and severe substance use disorder (SUD) is controversial, and few studies have examined the long-term
psychosocial outcome of these treatments. Our aim was to investigate whether pharmacological treatment was
associated with improved long-term psychosocial outcomes.
Methods: The present naturalistic study consisted of a long-term follow-up of 60 male patients with ADHD and
comorbid severe SUD; all participants had received compulsory inpatient treatment due to severe substance
abuse. The average interval between inpatient discharge and follow-up was 18.4 months. Thirty patients had
received pharmacological treatment for ADHD, and 30 patients were pharmacologically untreated. The groups
were compared with respect to mortality and psychosocial outcomes operationalized as substance abuse status,
ongoing voluntary rehabilitation, current housing situation and employment status.
Results: The groups were comparable with regard to the demographic and background characteristics. Overall,
mortality was high; 8.3% of the participants had deceased at follow-up (one in the pharmacologically treated
group and four in the untreated group; the between-group difference was not signiﬁcant). The group that
received pharmacological treatment for ADHD exhibited fewer substance abuse relapses, received more
frequently voluntary treatments in accordance with a rehabilitation plan, required less frequent compulsory
care, were more frequently accommodated in supportive housing or a rehabilitation center, and displayed a
higher employment rate than the non-treated group.
Conclusions: The recommendations for the close clinical monitoring of high-risk populations and the prevention
of misuse and drug diversion were fulﬁlled in the structured environment of compulsory care for the treated
group. Pharmacological treatment of ADHD in individuals with severe SUD may decrease the risk of relapse
and increase these patients' ability to follow a non-pharmacological rehabilitation plan, thereby improving
their long-term outcomes.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ided by The National Board of
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Attentiondeficithyperactivitydisorder (ADHD) isaneurodevelopmental
disorder that is characterized by hyperactivity and deﬁciencies in
impulse control, as well as difﬁculties with sustained attention and
distractibility. Endophenotypically, ADHD frequently involves impair-
ments in executive functioning, such as planning and organizing
actions, and in the regulation of emotions andmotivation. Coexisting dis-
orders, such as substance use disorder (SUD), are common for ADHD. In
adults, the prevalence of ADHD in the general population is estimated to
be between 2 and 4% (Fayyad et al., 2007); however, the prevalence of
ADHD in adults with SUD is estimated to be as high as 20 to 50%
(Gordon, Tulak, & Troncale, 2004; Sullivan & Rudnik-Levin, 2001; van
Emmerik-van Oortmerssen et al., 2012). Conversely, the prevalence of
SUD among ADHD patients is estimated to be approximately 50%. Thus,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Rudnik-Levin, 2001; Wilens et al., 2011). Additional and independent
predictors of SUD are conduct disorder (CD) during childhood and
antisocial personality disorder (ASPD) during adulthood (Hopfer et al.,
2013; Rodgers et al., 2014; Saban, Flisher, Laubscher, London, &
Morojele, 2014).
In nearly allmajor life activities, ADHD is associatedwith considerable
functional impairments, which include academic underachievement,
occupational limitations and difﬁculties with social and family life
(Gordon et al., 2004; Sullivan & Rudnik-Levin, 2001; van Emmerik-van
Oortmerssen et al., 2012). These impairments are also found in indi-
viduals with SUD. In a previously published study (BihlarMuld, Jokinen,
Bolte, & Hirvikoski, 2013), we conducted a clinical characterization of
patients with ADHD and comorbid severe SUD compared with patients
who exhibited severe SUD without known ADHD and patients with
ADHD without severe SUD. Overall, both the ADHD/SUD and SUD
groups attained a low educational level and minimal work experience;
however, the ADHD/SUD group exhibited earlier and more persistent
antisocial behaviors and abused stimulants more often than individuals
with severe SUD without known ADHD. Compared with patients with
ADHD without severe substance abuse, the ADHD/SUD group reported
more ADHD symptoms during childhood and exhibited poorer general
cognitive capacity (Bihlar Muld et al., 2013).
Pharmacological treatments for ADHD effectively reduce ADHD
symptoms (Castells et al., 2011; Koesters, Becker, Kilian, Fegert, &
Weinmann, 2009; Peterson, McDonagh, & Fu, 2008) and improve the
daily functioning and quality of life of ADHD patients (Buitelaar et al.,
2012; Rosler et al., 2013). Long-termbeneﬁcial effects of these pharmaco-
logical treatments on both symptom reduction and life functioning have
also been reported (Fredriksen, Halmoy, Faraone, & Haavik, 2012).
ADHD-speciﬁc treatments reduce the negative impact of ADHD on life
functioning; however, these treatments do not necessarily restore life
functioning to the level of healthy controls (Shaw et al., 2012). Fewer
improvements have been found with regard to substance use, antisocial
behavior, theuse ofmental health services andoccupational impairments
(Shaw et al., 2012). As a result, in patientswith ADHDand comorbid SUD,
pharmacological treatments have exerted a moderate or negligible effect
on ADHD symptoms; however, the effect of these treatments on
substance abuse is uncertain (Castells et al., 2011; Cunill, Castells, Tobias,
& Capella, 2014;Wilens et al., 2005). One naturalistic study indicated that
ongoing SUDwas the primary reason for the discontinuation of stimulant
medication (Torgersen, Gjervan, Nordahl, & Rasmussen, 2012). However,
recent studies of adult male long-term inmates with SUD have shown
that methylphenidate (MPH) reduces ADHD symptoms and improves
global functioning, quality of life, and cognitive functions (Ginsberg,
Hirvikoski, Grann, & Lindefors, 2012). Furthermore, Konstenius et al.
(2013) found that ADHDsymptoms and the risk for relapsewere reduced
in criminal offenders with ADHD and comorbid amphetamine abuse
after MPH treatment (Konstenius et al., 2013). In this randomized
control trial (RCT), individualized treatment protocols were adminis-
tered with reference to decreased dopamine function in addicted
subjects (Volkow, Fowler, Wang, & Swanson, 2004).
The availability of pharmacological treatments for individuals with
ADHD and comorbid severe SUD may be limited by the controversy
concerning the risks of prescribing stimulant medications to adults
with ADHD and SUD, such as the potential misuse and abuse of
prescribed stimulants and drug diversion (Bukstein, 2008; Faraone &
Wilens, 2007; Kollins, 2008; Sepulveda et al., 2011). The factors that
have been found to be critical for the individual assessment of risk
include the patient's age, severity of both ADHD and SUD, comorbidity
of conduct disorder or antisocial personality disorder, and past history
of medication compliance (Klassen, Bilkey, Katzman, & Chokka, 2012;
Kollins, 2008; Mariani & Levin, 2007; Perez de Los Cobos, Sinol, Perez,
& Trujols, 2012).
In Sweden, approximately 1000 individuals per year are required
to complete compulsory treatment for severe substance abuse inaccordance with the Care of Alcoholics and Drug Abusers Act (LVM).
The legislated duration of compulsory care is 6 months. The National
Board of Institutional Care (SiS) is the authority that is responsible for
the compulsory treatment of adults with substance abuse. The aim of
the present study was to explore whether pharmacological treatment
was associated with improved long-term psychosocial outcome using
an observational follow-up study design. This study included a cohort
of adult maleswith ADHDwhowere undergoing compulsory treatment
for severe SUD; the same cohort was characterized in a previously
published study (Bihlar Muld et al., 2013).
2. Methods
2.1. Study setting
This follow-up study was conducted between February 2008 and
February 2009. All participants underwent compulsory care between
2004 and 2008 at SiS Institution Hornö in Enköping, Central Sweden.
The target patient population of the SiS Institution Hornö is adult male
patients who, in addition to substance abuse, have a history of violence
or other severe psychiatric comorbidities. This study was approved by
the Regional Ethics Committee of Stockholm (42-790-2012).
2.2. Participants
The patients came from different counties in Sweden and had been
placed in a central unit of SiS. Fig. 1 describes the enrolment of the
study participants. Between 2004 and 2008, 413 individualswere treated
at the SiS InstitutionHornö. Of the 71 patients referred for assessment, 47
were diagnosedwith ADHD. In addition, 13 of the assessed patients were
diagnosedwith ADHD prior to admission to the institution andwere also
included in this study. Thus, the total number of participants in our study
was 60; all were adult males with ADHD and comorbid severe SUD and
were characterized in a previously published study (Bihlar Muld et al.,
2013). The mean age of the participants was 26.25 years (SD = 6.02,
range = 20–46 years) upon admission to the SiS Institution Hornö.
2.3. Procedures
2.3.1. General treatment goal at SiS Institutions
The purpose of treatment at SiS Institutions is detoxiﬁcation, mental
state stabilization, social, psychological and diagnostic assessment,
motivational intervention, rehabilitation planning and transfer to a
voluntary rehabilitation facility.
2.3.2. Diagnostic assessment
The diagnosis of ADHD was based on the DSM-IV-TR criteria
(American Psychiatric Association, 2000) in all cases. The diagnostic
assessment included multiple sources of information, including clinical
interviews, standardized self-rating questionnaires such as the Wender
Utah Rating Scale (WURS) (Ward,Wender, & Reimherr, 1993), collateral
information from questionnaires, clinical interviews with the partici-
pants' signiﬁcant others and additional information from medical
records pertaining to child, adolescent and adult psychiatric services
(when available). Although neuropsychological testing was not used
to establish a diagnosis of ADHD, all diagnostic assessments included
cognitive testing. The diagnosis of ADHDwas established after a consen-
sus was reached between either two to three experienced clinical
psychologists from the institution or the investigative psychologist and
a consulting specialist in neuropsychology. Standardized and validated
rating scales and interviews, such as the Beck Depression Inventory
(BDI), the Beck Anxiety Inventory (BAI), the Symptoms Checklist (SCL-
90), and the Structured Clinical Interview for DSM Disorders (SCID-I),
were used for the assessment of comorbid disorders (Beck & Steer,
2005; Beck, Steer, & Brown, 2005; Degoratis & Melisaratos, 1983; First
& Herlofson, 1998). In patients with severe comorbidity, the diagnosis
Assessment of ADHD in referred 
cases, n=71
No ADHD diagnosis, n=11
Diagnosed with ADHD, n=60
Unique cases in 2004–2008,
n=413
No diagnostic assessment,
n=199; diagnostic
assessment but no 
assessment for ADHD, n=
143
Re-admission of the same
individual two or more
times, n=177
Total enrolled at Institution Hornö in
2004–2008, n=590
22 allocated to treatment at SiS
Institution Hornö;
8 treated at a local psychiatric clinic.
25 referred to a local clinic but never
received treatment; 5 patients declined
to be referred. 
Non-randomized allocation to
pharmacological treatment
Long-term follow-up
n=30 (100%) reached and included
in the follow-up.
n=22 complete and n=8 partial follow-
up data. 
Data analysis
The pharmacologically non-treated
group: n=30 in the statistical analyses.
The pharmacologically treated
group: n=30 in the statistical
analyses.
Fig. 1. Flowchart describing the enrollment of the participants.
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multiple data source, consensus-based diagnostic assessment was the
standard in Sweden during the study period. The assessment procedures
have been described in further detail in our previously published study
(Bihlar Muld et al., 2013; First & Herlofson, 1998). In case of previous
diagnosis of ADHD, the clinical procedure was to indent the previous
medical records to SiS Institution Hornö. The aim was to validate the
ADHD diagnosis before the patients were referred to a clinic within
their hometown for pharmacological treatment. There were no large
differences in diagnostic procedures between the individuals with
previous diagnosis of ADHD (n= 13) and the individuals diagnosed at
SiS Institution Hornö (n= 47).
2.3.3. Rehabilitation planning
During the legislated 6-month period of compulsory care, a rehabili-
tation plan that was based on the relevant clinical and psychosocial
assessments was generated for each patient. The rehabilitation plan
was individualized and based on the assessed need for rehabilitation
and each patient's motivation to perform voluntary rehabilitation after
completion of compulsory care. The rehabilitation options included
rehabilitation institutions, family homes and supportive housing (all
settings which provide 24-hour care). All rehabilitation options were
covered by the social services agency in each patient's local municipality.For patientswho had their own accommodations and a sufﬁcient level of
psychosocial functioning, outpatient care was offered as an option. All
rehabilitation options included or were supplemented with psychiatric
treatment and drug screening, except for six participants in supportive
housing who refused or did not require parallel psychiatric treatment.
2.3.4. Pharmacological treatment
The patients who were diagnosed with ADHD were referred to a
neuropsychiatric clinic or an addiction disorders clinic within the
patient's hometown for pharmacological treatment, except for six
patients who declined to be referred. These six patients were provided
with the possibility of future referral. In all referred cases, the medical
staff at SiS Institution Hornö contacted the patient's local clinic to
initiate pharmacological treatment for ADHD, including themedications
to be prescribed by the local clinic, during the compulsory care period at
SiS Institution Hornö. The allocation of patients to these treatment
groups is shown in Fig. 1.
2.4. Measures
2.4.1. Demographic and background data
The demographic and background data were obtained from the
evaluation and documentation system (DOK), which is based on semi-
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substance abuse. The DOK interviews are voluntary assessments that
are performed upon admission to compulsory care and regard back-
ground information including life-time psychiatric symptoms. In the
ADHD/SUD group, 22 of 60 participants had never participated in a DOK
interview; in these cases, the data were obtained from the clinical assess-
ments that were conducted subsequently during the compulsory care
period. The DOK interview assessments and the clinical assessments
have been described in detail in our previously published study (Bihlar
Muld et al., 2013).
2.4.2. Long-term follow-up and outcomes
The follow-up datawere collected between February 2008 andMarch
2009. The time between discharge from the institution and the beginning
of the follow-up period ranged from 6 to 45 months (M= 18.4 months,
median = 16 months, SD = 9.79 months).
The follow-up assessment began by contacting and interviewing the
local social worker for each patient. In 46 cases, the patient maintained
contact with the social services agency. Five of the 14 patients who no
longer maintained contact with the social services agency were
deceased. An additional ﬁve participants could not be tracked, either
through their social workers or the tax authority's population registers;
for four of these patients, it was possible to obtain information from
their former local socialworkers regarding some aspects of their current
social situation. The follow-up interviews with the patients took the
form of either face-to-face meetings or telephone interviews. The
questions that were asked during the interviews with the patients'
social workers (and the patients who could be reached) were semi-
structured. The topics that were surveyed are described below.
The current abuse status was categorized as no known substance
abuse at the time of follow-up, no abuse due to compulsory care
(e.g., imprisonment, forensic care, or a new period of compulsory care
for substance abuse) or ongoing substance abuse.
2.4.2.1. Rehabilitation status. Patients who did not require rehabilitation
due to good psychosocial functioningwere deﬁned as having a combina-
tion of no substance abuse, independent accommodation (which, in
some cases, included supportive housingwithout psychiatric treatment)
and current employment. Voluntary rehabilitation included long-term
stays at an abuse rehabilitation center (24-hour care), a rehabilitation-
oriented family home or supportive housing that included regular
psychiatric care. Compulsory carewas deﬁned as imprisonment, forensic
care or a new period of compulsory care for substance abuse at the time
of the follow-up assessment. No rehabilitation due to other reasons
included all patients who did notmeet the rehabilitation criteria deﬁned
above, including patients exhibiting ongoing drug abuse, or homeless-
ness, and those who could not be found.
The accommodation statuswas categorized as independent accommo-
dation, rehabilitation center or family home (24-hour care), supportive
accommodation or compulsory care, as deﬁned above.
Employment status included two primary categories: employed and
unemployed. The participants were considered to be employed if they
participated in any form of structured and regular work or schooling.
The unemployed participants were separated into subcategories that
were related to the cause of unemployment (e. g., compulsory care,
voluntary rehabilitation, sick leave and other reasons).
2.5. Statistical analyses
To investigate whether differences in long-term outcomes could be
explained by differences at the time of compulsory care, the two groups
(i.e., those who received pharmacological treatment for ADHD and
those who did not) were compared regarding their demographic and
background characteristics. Student's t-test was used for continuous
variables, and the chi-squared test was used for categorical variables.
On the t-tests, the degrees of freedom were corrected for unequalvariance if indicated by Levene's test for the equality of variance. The
effect sizes for the t-tests were expressed as Cohen's d (Cohen, 1988)
and interpreted as follows: approximately .3 for a “small” effect, approxi-
mately .5 for a “medium” effect, and ≥ .8 for a “large” effect. The effect
sizes for the chi-squared tests were expressed asΦ (phi) and interpreted
as a weak association (.10–.20), a moderate association (.20–.40), a
relatively strong association (.40–.60), a strong association (.60–.80)
or a very strong association (N .80) (Cohen, 1988). When comparing
the groups regarding their psychosocial outcome variables, chi-
squared tests were used. Multiple regression analysis was performed
to adjust for the potential effect of follow-up interval on outcome
measures. Individuals for which data were missing and deceased indi-
viduals were excluded using pairwise exclusion from the analyses of
long-term outcomes. The alpha level was set at .05. The statistical
analyses were performed using the SPSS statistical software package
(IBM, SPSS™, version 20).
3. Results
Fig. 1 describes the enrolment of the participants in the ADHD/SUD
group from SiS Institution Hornö. Among the 413 unique cases treated
at SiS Institution Hornö between 2004 and 2008, assessments for
ADHD were conducted on 71 patients, 13 of whom had previously
been diagnosed with ADHD before admission and 47 of whom were
diagnosed with ADHD at SiS Institution Hornö. Depending on the pre-
requisites and guidelines at their local clinic, 30 patients received phar-
macological treatment for ADHD, and 30 patients did not receive
pharmacological treatment. Of those patients who were being pharma-
cologically treated at the time of the follow-up evaluation, 22 patients
had already begun pharmacological treatment for ADHD at SiS Institu-
tion Hornö (utilizing prescriptions from their local clinic), whereas
eight patients began treatment at a local outpatient clinic after dis-
charge. Thirty patients never began pharmacological treatment for
ADHD. The reasons (when known) why these patients never started
treatment are presented in a table within the supplementary materials.
3.1. Demographic and background characteristics
No statistically signiﬁcant differences were found between the two
groups in childhood conditions, IQ, educational level, work experience,
history of treatment interventions or self-reported psychiatric symptoms,
reported at admission to the SiS Institution Hornö (Tables 1–3).
3.2. Long-term outcomes
The follow-up intervalwas not a signiﬁcant predictor of the patients'
rehabilitation status, substance abuse status, accommodation status or
employment status (all p-values N .10).
Table 4 compares the long-term outcome measures between the
treated and non-treated ADHD groups.
3.2.1. Mortality
Upon the follow-up assessment, 5 of the 60 patients (8.3%) had
deceased. The mean age at death was 25.0 years (SD = 3.8). No
statistically signiﬁcant difference in mortality was found between the
two groups.
3.2.2. Substance abuse status
Our results indicate that relapses into substance abuse were signiﬁ-
cantly less frequent in the pharmacologically treated ADHD group than
in the group that was not treated for ADHD (p= .01) (Table 4).
3.2.3. Rehabilitation status
Non-rehabilitation due to good psychosocial functioning was twice
as frequent in the pharmacologically treated group (20%) than in the
untreated group (10%). Voluntary treatment at the time of the follow-
Table 1
Family background, education and work experience of the two groups of patients with ADHD and comorbid SUD in compulsory care: the pharmacologically treated group and
the non-pharmacologically treated group.
Pharmacologically treated n = 30 Untreated n = 30 χ2 p Φ
Family background
Custodian other than biological parents 1 (3.3%) 2 (6.7%) .87 .83 .12
Single parent 7 (23.3%) 5 (16.7%)
Parents separated before the patient was 18 years old 13 (43.3%) 15 (50.0%)
Both parents 9 (30.0%) 8 (26.7%)
Psychiatric disorder and/or substance abuse among parents
Psychiatric disorder and/or substance abuse among parents 18 (60.0%) 14 (46.7%) .59 .44 .10
No psychiatric disorder and/or substance abuse in parents 12 (40.0%) 14 (46.7%)
Missing data 0 2 (6.7%)
Educational level
Less than 9 years 6 (20.0%) 6 (20.0%) .40 .82 .08
9 years 18 (60.0%) 16 (53.3%)
Secondary school/vocational education 6 (20.0%) 8 (26.7%)
Work experience
Work experience ≤6 months 9 (30.0%) 14 (46.7%) 5.3 .07 .31
Work experience 6–24 months 8 (26.7%) 2 (6.7%)
Work experience N24 months 13 (43.3%) 8 (26.7%)
Missing data 0 6 (20.0)
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group (36.7%) than in the untreated group (6.7%). Compulsory care
was less frequent in the pharmacologically treated group (3.3%) than
in the non-treated group (20%) (p= .01).3.2.4. Accommodation status
Nearly 57% of the patients in the pharmacologically treated group
were residing in supportive housing or a rehabilitation center, com-
pared with just over 13% of those in the untreated group. Additionally,
30% of the patients in the untreated group were homeless or resided
in compulsory care, compared with 10% of those in the treated group
(p = .028).3.2.5. Employment status
Because 60% of the participants were undergoing compulsory care
or voluntary rehabilitation or were on sick leave, the employment
status was relevant for only 24 participants (15 patients in the treated
group and 9 patients in the non-treated group). Overall, 20% of the
patients in the treated group and 13.3% of the patients in the untreated
groupwere employed, whereas 30% of the patients in the treated group
and 16.5% of the patients in the untreated group were unemployed
(p= .028).Table 2
Previous rehabilitation, treatment intervention, and psychiatric care in the two groups of patien
group and the non-pharmacologically treated group.
Pharmacologicall
Special pedagogical support in primary school
Special pedagogical support in primary school 11 (36.7%)
No special pedagogical support 18 (60.0%)
Missing data 1 (3.3%)
Compulsory care during childhood
Compulsory care 14 (46.7%)
No compulsory care 16 (53.3%)
Missing data 0
Previous imprisonment
Imprisonment 23 (76.7%)
No imprisonment 7 (23.3%)
Missing data 0
Previous adult psychiatric care (in addition to care due to SUD)
Psychiatric care during adulthood 19 (63.3%)
No psychiatric care during adulthood 10 (33.3%)
Missing data 1 (3.3%)4. Discussion
To the best of our knowledge, this is the ﬁrst long-term follow-up
study of individuals with ADHD and severe SUD after compulsory care
for SUD. In this naturalistic study, the group that had received pharma-
cological treatment for ADHD exhibited better long-term outcomes on
all measures of functioning than the non-treated group. Mortality was
high in the entire study group; however, mortality did not signiﬁcantly
differ between the two groups.4.1. Functional outcome measures
Pharmacological treatment for ADHD has been shown to effectively
reduce ADHD symptoms in several short-term randomized controlled
trials (Castells et al., 2011; Koesters et al., 2009; Peterson et al., 2008);
however, the results of studies that included individuals with ADHD
and comorbid SUD have been inconclusive (Castells et al., 2011; Wilens
et al., 2005). Few studies have evaluated the long-term effects of phar-
macotherapy on functional outcome (Fredriksen et al., 2012). Functional
outcome measures may better characterize the long-term outcome of
patients with chronic disorders that display complex symptomatology,
such as ADHD, than measures of symptom reduction (Rostain, Jensen,
Connor, Miesle, & Faraone, 2013). The patients in the present studytswith ADHD and comorbid SUD in compulsory care (LVM): the pharmacologically treated
y treated n = 30 Untreated n = 30 χ2 p Φ
11 (36.7%) .00 1.0 .00
18 (60.0%)
1 (3.3%)
12 (40.0%) .17 .68 .05
17 (56.7%)
1 (3.3%)
18 (60.0%) .70 .40 .11
9 (30.0%)
3 (10.0%)
19 (63.3%) .15 .70 − .05
8 (26.7%)
3 (10.0%)
Table 3
Clinical characteristics in the two groups of patients with ADHD and comorbid SUD: the pharmacologically treated group and the non-pharmacologically treated group.
Pharmacologically treated n = 30 Untreated n = 30 t or χ2 p d or Φ
Self-reported hallucinations and other psychotic symptoms (life-time)
Hallucinations and other symptoms of psychosis 16 (53.3%) 19 (63.3%) 1.71 .19 − .17
No hallucinations or other symptoms of psychosis 11 (36.7%) 9 (30.0%)
Missing data 3 (10.0%) 2 (6.7%)
Self-reported symptoms of depression and anxiety (life-time)
Symptoms of depression/anxiety 23 (76.7%) 28 (93.3%) 3.14 .08 − .24
No symptoms of depression/anxiety 5 (16.7%) 1 (3.3%)
Missing data 2 (6.7%) 1 (3.3%)
Preferred substance of abuse
Heroin 6 (20.0%) 5 (16.7%) .84 .99 .12
Amphetamines 15 (50.0%) 14 (46.7%)
Cocaine 1 (3.3%) 2 (6.7%)
Alcohol 2 (6.7%) 2 (6.7%)
Hashish/marijuana 3 (10.0%) 2 (6.7%)
GHB 2 (6.7%) 1 (3.3%)
Benzodiazepines 1 (3.3%) 1 (3.3%)
Missing data 0 3 (10%)
Self-reported ADHD symptoms M (SD) M (SD)
WURS score 61.20 (15.8) 58.95 (19.2) − .44 .66 .131
Missing information 5 (16.7%) 8 (26.7%)
Cognitive functions (WAIS-III)
Full scale IQ (FSIQ) 88.8 (8.81) 87.4 (9.1) − .55 .58 .157
Verbal IQ (VIQ) 87.8 (9.5) 87.2 (8.9) − .23 .82 .066
Performance IQ (PIQ) 91.9 (10.6) 90.4 (11.4) − .48 .64 .135
Verbal Comprehension Index (VCI) 88.9 (8.7) 91.5 (10.1) .99 .33 .279
Perceptual Organization Index (POI) 93.3 (20.8) 93.3 (12.9) − .02 .99 .004
Working Memory Index (WMI) 87.6 (12.9) 82.2 (12.5) −1.52 .13 .436
Processing Speed Index (PSI) 81.7 (10.6) 81.7 (10.6) − .55 .59 .161
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by early and persistent antisocial behavior, poor cognitive capacity,
extensive psychiatric comorbidity and low psychosocial functioningTable 4
Follow-up results for the rehabilitation group and the non-rehabilitation group regarding
employment status.
All Pharmac
N = 60
Mortality
Deceased at follow-up 5 (8.3%) 1 (3.3%)
Substance abuse status
No known substance abuse at follow-up 32 (53.3%) 23 (76.7
No substance abuse due to compulsory care 7 (11.7%) 1 (3.3%)
Ongoing substance abuse 9 (15.0%) 5 (16.7%
Deceased at follow-up 5 (8.3%) 1 (3.3%)
Missing data 7 (11.7%) 0
Rehabilitation status
No rehabilitation due to good psycho-social functioning 9 (15.0%) 6 (20.0%
Voluntary rehabilitation 13 (21.7%) 11 (36.7
Compulsory care 7 (11.7%) 1 (3.3%)
No rehabilitation due to other reasons 26 (43.3%) 11 (36.7
Deceased at follow-up 5 (8.3%) 1 (3.3%)
Accommodation status
Own housing 17 (28.3%) 9 (30.0%
Rehabilitation center/family home 10 (16.7%) 8 (26.7%
Supportive housing 11 (18.3%) 9 (30.0%
Compulsory care 7 (11.7%) 1 (3.3%)
Homeless 5 (8.3%) 2 (6.7%)
Deceased at follow-up 5 (8.3%) 1 (3.3%)
Missing data 5 (8.3%) 0
Employment status
Employed or studying 10 (16.7%) 6 (20.0%
No employment 14 (23.3%) 9 (30.0%
In voluntary rehabilitation 13 (21.7%) 11 (36.7
In compulsory care 7 (11.7%) 1 (3.3%)
On sick-leave 3 (5.0%) 2 (6.7%)
Deceased at follow-up 5 (8.3%) 1(3.3%)
Missing data 8 (13.3%) 0
Note: The numbers of individuals with missing data and deceased individuals are shown for th
using pairwise exclusion. The p-values presented in bold indicate a statistically signiﬁcant diffe(Bihlar Muld et al., 2013). Therefore, the present study evaluated the
long-term functional outcomes of these patients after their discharge
from compulsory care.mortality, substance abuse status, rehabilitation status, accommodation status and
ologically treated n = 30 Untreated n = 30
χ2 p Φ
4 (13.3%) 1.96 .16 − .18
%) 9 (30.0%) 8.08 .02 .41
6 (20.0%)
) 4 (13.3%)
4 (13.3%)
7 (23.3%)
) 3 (10.0%) 13.22 .01 .47
%) 2 (6.7%)
6 (20.0%)
%) 15 (50.0%)
4 (13.3%)
) 8 (27.7%) 10.88 .028 .47
) 2 (6.7%)
) 2 (6.7%)
6 (20.0%)
3 (10.0%)
4 (13.3%)
5 (16.7%)
) 4 (13.3%) 12.55 .028 .49
) 5 (16.7%)
%) 2 (6.7%)
6 (20.0%)
1 (3.3%)
4 (13.3%)
8 (27.7%)
e psychosocial outcome measures; these data were excluded from the statistical analyses
rence.
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Twenty-two of the 30 patients (73.3%) in the pharmacologically
treated group began treatment for ADHDduring a compulsory inpatient
care period. The compulsory care setting facilitated the structured and
monitored initiation of pharmacological treatment, which included
drug screening, daily observations of each patient's mental state and
response to the medication, and daily support and feedback regarding
behavioral improvements. Initiating the pharmacological treatment at
this institution may have reduced the risk for relapse during the vulnera-
ble period immediately after discharge. Moreover, the patients may have
also been more likely to select a voluntary rehabilitation option after
discharge as a result of the beneﬁts of multimodal treatment.
The institutional context in compulsory care for substance abuse
corresponds to a prison context, as it pertains to a structured environment
and treatmentmonitoring (Ginsberg & Lindefors, 2012). Additionally, the
clinical characteristics of our study group, including the cognitive, psycho-
social and comorbidity proﬁles, were similar to those of prison inmates
with ADHD and SUD (Bihlar Muld et al., 2013; Ginsberg, Hirvikoski, &
Lindefors, 2010). In previous studies, both symptom reduction and
functional improvements were observed in inmates with ADHD after
treatment with stimulant medication (Ginsberg et al., 2012; Konstenius
et al., 2013). Thus, utilizing an institutional setting as an environment
for the initiation of pharmacological treatment may be beneﬁcial for
severely disabled patients with ADHD and comorbid severe SUD.
4.3. Risks, beneﬁts and treatment needs
The patient population with ADHD, SUD and persistent antisocial
behavior is a group that is at high risk for the misuse and diversion of
prescribed psycho-stimulants (Kollins, 2008; Rabiner, 2013; Wilens
et al., 2008). Undoubtedly, it is a challenging task for clinicians to
balance the pharmacologic needs of these patients with the risk of
drug misuse and diversion (Mariani & Levin, 2007). In the current
study, only half of the patients received pharmacological treatment for
ADHD, which may be partially attributable to these risks.
The current guidelines for the treatment of ADHD (Bolea-Alamanac
et al., 2014; Kooij et al., 2010; National Institute for Clinical Exellence,
2008) recommend non-stimulant medication as the ﬁrst-line treatment
for patients with ADHD and comorbid SUD. Additionally, close monitor-
ing, the avoidance of short-acting stimulants and additional psychological
treatments have beenproposed to reduce the risks of abuse andmisuse of
prescribed stimulants (Klassen et al., 2012; Kollins, 2008; Mariani &
Levin, 2007; Perez de Los Cobos et al., 2012).
Nevertheless, these risks should be weighed against the potential
beneﬁts of pharmacologic treatment, which include a decrease in crimi-
nality (Lichtenstein et al., 2012), a reduction in relapses, and better
long-term functional outcomes in high-risk patients during pharmaco-
logic ADHD treatment (Ginsberg et al., 2012). The mortality rate was
high in the present study group. Moreover, this severely disabled patient
group appears to be at risk for lifelong social exclusion. Thus, it is impor-
tant to strive to improve the clinical care of this patient population
(National Institute for Clinical Exellence, 2008). Both pharmacological
and non-pharmacological treatment modalities (Hirvikoski, Waaler,
Lindstrom, Bolte, & Jokinen, 2014; Hirvikoski et al., 2011) should be
adjusted to the individual characteristics of each patient with ADHD
and comorbid severe SUD.
4.4. Risk for confounding by indication
Because this study did not include a randomized design, it is possible
that the association between the positive outcomes and the pharmaco-
logical treatment could be explained by differences in the baseline
clinical characteristics. However, no between-group differences were
detected at baseline. Furthermore, both the pharmacologically treated
and non-treated groups had been sentenced to compulsory care onthe same basis and were diagnosed according to the same assessment
procedures. Moreover, the protocols for referral were identical.
Although we cannot exclude the potential confounding resulting from
the naturalistic design of this study, it does not appear to be plausible
that background characteristics adequately explain the differences
between the two groups in their long-term psychosocial outcomes.4.5. Mortality and missing data
Mortality was high in the entire study group. The cause of death of
the deceased patients was not reported because objective data could
not be obtained from the Causes of Death Register. However, a common
cause of death in patients with severe drug abuse, such as heroin abuse,
is drug overdose. Our previous study (Bihlar Muld et al., 2013) of the
same cohort of patients showed that that multiple drug abuse was
common in this cohort; this characteristic may increase the risk of
mortality due to drug overdose.
All of the patients who had no contact with social services or could
not be reached were in the untreated group. This ﬁnding implies that
the actual rate of ongoing drug abuse in theuntreated group is unknown.
However, in accordance with clinical experience and anecdotal informa-
tion from their social workers, these patients were assumed to have
relapsed into substance abuse. The differences at baseline (i.e., in the
background characteristics) between the reachable and non-reachable
patients could not be analyzed due to the small number of cases in
the non-reachable group.4.6. Limitations
One limitation of the naturalistic design of the present study was
that the follow-up intervals differed between the two groups; however,
this difference was not statistically signiﬁcant and the follow-up
interval was not a signiﬁcant predictor of any of the psychosocial out-
comemeasures.Moreover, despite the relatively long follow-up interval
in the present study, many of the patients were continuing their
planned rehabilitation at the time of the follow-up assessment. An
even longer follow-up interval would have provided data on psychoso-
cial outcomes after the rehabilitation context. Furthermore, the propor-
tion of missing data was relatively high in the non-treated group, and
we excluded individuals forwhich dataweremissing from the analyses.
Based on our clinical experience and the information from patients'
social workers, we assume that many of the patients who either did
not respond to our attempts to contact them or could not be reached
had relapsed. If this assumption is correct, the differences between the
pharmacologically treated group and the non-treated group would be
even greater. One further limitation of this study was that the data on
pharmacological treatments were limited because we had no data
regarding the details of the treatment regimen or information on the
potential misuse or diversion of the prescribed medications. An
additional limitation may be the generalizability of these results. The
present study group was characterized by an extensive clinical burden,
including persistent antisocial behaviors and high frequency of life-time
substance use induced psychotic symptoms (in case of psychotic symp-
toms at admission, these generally disappeared after the detoxication
and stabilization period). These attributes may not characterize the
total population of individuals with ADHD and comorbid SUD. Further-
more, the study context of compulsory care due to SUD has no equiva-
lent in most other countries. In this regard, the generalizability of our
results is limited. However, individuals who exhibit a high symptom
severity of both ADHD and SUD, in addition to comorbid psychiatric
symptoms, are often found in other compulsory care settings, such as
forensic care and institutional youth care, and in voluntary outpatient
and inpatient addiction and psychiatric clinics (Klein et al., 1997; Rosler
et al., 2004; Torok, Darke, & Kaye, 2012; Wilens et al., 2008).
89B. Bihlar Muld et al. / Journal of Substance Abuse Treatment 51 (2015) 82–904.7. Conclusions and clinical implications
The present study suggests that the pharmacological treatment of
ADHD may improve the long-term outcomes of individuals with
ADHD and severe comorbid SUD after discharge from compulsory
care. An institutional treatment setting during the initiation of pharma-
cological treatment may decrease the risk for relapse and increase the
patient's motivation and ability to follow the corresponding non-
pharmacological rehabilitation plan after discharge. In high-risk popula-
tions, close clinical monitoring is important for not only treatment
compliance but also the prevention of drug misuse or diversion.
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